Results 91 to 100 of about 1,522,500 (352)

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Single-Nucleotide Polymorphisms in Host Pattern-Recognition Receptors Show Association with Antiviral Responses against SARS-CoV-2, in-silico Trial

Journal of Medical Microbiology and Infectious Diseases, 2020
Introduction: Coronavirus infectious disease 2019 (COVID-19) is a viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pathogen-associated molecular patterns (PAMPs) can be detected by host pattern-recognition receptors
Hossein Teimouri, Amirhosein Maali
doaj  

The Association Between ANKRD55 rs6859219 SNP and the Risk of Multiple Sclerosis in Iranian Patients

Caspian Journal of Neurological Sciences, 2021
Background: Multiple Sclerosis (MS) is a neuroinflammatory autoimmune disease of the central nervous system. ANKRD55 rs6859219 Single Nucleotide Polymorphisms (SNPs) are reported as a potential novel MS risk gene, but the biological reasons underlying ...
Sepideh Mandegarfard, Arash Pourgholaminejad, Seyed Mohsen Miresmaeili, Seyed Abolhassan Shahzadeh Fazeli   +3 more
doaj  

Cytokine gene polymorphism (interleukin-1β +3954, Interleukin-6 [−597/−174] and tumor necrosis factor-α −308) in chronic periodontitis with and without type 2 diabetes mellitus

Indian Journal of Dental Research, 2014
Background: Pro-inflammatory cytokine gene polymorphisms are potential candidates for susceptibility for both type 2 diabetes mellitus (DM) and chronic periodontitis (CHP).
Nitin Sharma, Rosamma Joseph, R Arun, R Chandni, K Lekshmy Srinivas, Moinak Banerjee   +5 more
doaj   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Genetically Determined Plasma Lipid Levels and Risk of Diabetic Retinopathy: A Mendelian Randomization Study. [PDF]

, 2017
Results from observational studies examining dyslipidemia as a risk factor for diabetic retinopathy (DR) have been inconsistent. We evaluated the causal relationship between plasma lipids and DR using a Mendelian randomization approach.
Asian Genetic Epidemiology Network Consortium, Burdon, Kathryn P, Chen, Ching J, Chen, Yii-Der Ida, Cheng, Ching-Yu, Chong, Yong He, Christiansen, Mark W, Cotch, Mary Frances, Craig, Jamie E, Fan, Qiao, Gan, Alfred, Gudnason, Vilmundur, Guo, Xiuqing, Hai, Yang, Hancock, Heather, Hanis, Craig L, Huang, Yu-Chuen, Hung, Yi-Jen, Ipp, Eli, Jensen, Richard A, Jia, Yucheng, Kaidonis, Georgia, Kim, Jihye, Klein, Barbara EK, Klein, Ronald, Kuo, Jane, Lee, Wen-Jane, Li, Xiaohui, Liao, Wen-Ling, Liew, Gerald, Mitchell, Paul, Penman, Alan, Pollack, Samuela, Price, Alkes, Psaty, Bruce M, Rotter, Jerome I, Sandow, Kevin, Smith, Albert V, Sobrin, Lucia, Stanwyck, Lynn K, Tan, Gavin, Tsai, Fuu-Jen, Wang, Jie Jin, Wong, Tien Yin   +43 more
core   +1 more source

Data‐driven discovery of gene expression markers distinguishing pediatric acute lymphoblastic leukemia subtypes

Molecular Oncology, EarlyView.
This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh, Nikola Tom, Anna Schrøder Lassen, Helene Brasch Lind Petersen, Ulrik Kristoffer Stoltze, Karin Wadt, Kjeld Schmiegelow, Matteo Tiberti, Elena Papaleo   +8 more
wiley   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source